A Safe Immunosuppressive Protocol in Adult-to-Adult Living Related Liver Transplantation

Transplantation Proceedings

Volumn 38, Issue 4, 2006, Pages 1106-1108

  Gruttadauria, S ^a,b,c   Cintorino, D ^a,c   Piazza, T ^a,c   Mandala, L ^a,c   Doffria, E ^a,c   Musumeci, A ^a,c   Di Trapani, G ^a,c   Arcadipane, A ^a,c   Scianna, G ^a,c   Spada, M ^a,b,c   Verzaro, R ^a,c   Volpes, R ^a,c   Vizzini, G ^a,c   Palazzo, U ^a,c   Minervini, M ^a,c   Marsh, J W ^b,c   Marcos, A ^b,c   Gridelli, B ^a,b,c  

^a MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UMPC Health Plan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; METASTASIS; POSTOPERATIVE COMPLICATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RECIPIENT; RETRANSPLANTATION; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FAMILY; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SAFETY; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 33744789956     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.141     Document Type: Article

References (10)

1. Heffron T.G., Gruttadauria S., Campi O., et al. Surgical innovations in pediatric liver transplantation. reduced-size, split, and living-related transplantation. Prob Gen Surg 15 (1998) 104
2. Marcos A. Right lobe living donor liver transplantation. a review. Liver Transpl 6 (2000) 3
3. Ringe B., Moritz M., Zeldin G., et al. What is the best immunosuppression in living donor liver transplantation?. Transplant Proc 37 (2005) 2169
4. Gruttadauria S., Vasta F., Mandala L., et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 37 (2005) 2611
5. Gruttadauria S., Mandala L., Cintorino D., et al. Improvement in hepatic parenchymal transection for living related liver donor. Transplant Proc 37 (2005) 2589
6. Kahan B.D., Rajagopalan P.R., Hall M., et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody. Transplantation 67 (1999) 276
7. Ponticelli C., Yussim A., Cambi V., et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72 (2001) 1261
8. Lawen J.G., Davies E.A., Mourad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75 (2003) 37
9. Singh N., Paterson D.L., Gayowski T., et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. a randomized, controlled trial. Transplantation 70 (2000) 717
10. Marino I.R., Doria C., Scott V.L., et al. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. Transplantation 78 (2004) 886